Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
22
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | 30 | $8.63M | $74.1K | 2023-12-19 |
| Oaktree AZ Strategic Lending Fund, L.P. | 10% Owner | 1 | $0 | $0 | 2023-11-30 |
| Oaktree Specialty Lending Corp | 10% Owner | 1 | $0 | $0 | 2023-11-30 |
| BROOKFIELD Corp /ON/ | 10% Owner | 1 | $0 | $0 | 2023-11-30 |
| Allison David D. | Director | 3 | $0 | $0 | 2023-06-16 |
| Cline Darren S | Director | 2 | $0 | $0 | 2023-06-16 |
| Wilfong Diane E. | Director | 3 | $0 | $0 | 2023-06-16 |
| SHAH MAHENDRA | Director | 3 | $0 | $0 | 2023-06-16 |
| NELSON TIMOTHY S | Director | 4 | $107.6K | $0 | 2023-06-16 |
| Kalb Michael Wayne | CFO | 2 | $0 | $0 | 2023-05-10 |
| Hoekman John | Chief Scientific Officer | 12 | $0 | $0 | 2023-02-14 |
| Paolillo Leonard | Chief Commercial Officer | 3 | $0 | $0 | 2023-02-14 |
| Leaman John Harold | Chief Financial Officer | 7 | $0 | $0 | 2023-02-14 |
| ADAMS ADRIAN | COB, CEO and President | 6 | $279.9K | $0 | 2023-02-14 |
| PARKER H STEWART | Director | 17 | $0 | $0 | 2022-06-16 |
| SHREWSBURY STEPHEN B | Chief Medical Officer | 10 | $0 | $0 | 2022-03-29 |
| Kossow Jon Erik | 10% Owner | 5 | $12.38M | $0 | 2021-04-27 |
| PARMAR KUSH | 10% Owner | 11 | $8.63M | $0 | 2021-04-27 |
| venBio Global Strategic Fund II L.P. | 10% Owner | 8 | $6.75M | $0 | 2021-04-27 |
| KRAVIS HENRY R | 10% Owner | 4 | $16.50M | $0 | 2021-04-27 |
| ROCKLAGE SCOTT M | 10% Owner | 1 | $0 | $0 | 2021-04-22 |
| HAQUE PROMOD | 10% Owner | 1 | $0 | $0 | 2021-04-22 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-19 | 2023-12-19 | 208,657 | $0.08 | $16.7K | 2,029,495 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-19 | 2023-12-19 | 28,632 | $0.08 | $2.3K | 280,294 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-18 | 2023-12-19 | 28,682 | $0.11 | $3.2K | 308,926 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-18 | 2023-12-19 | 209,029 | $0.11 | $23.0K | 2,238,152 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-15 | 2023-12-19 | 87,934 | $0.29 | $25.5K | 2,447,181 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | S Sale | 2023-12-15 | 2023-12-19 | 12,066 | $0.29 | $3.5K | 337,608 | SEC↗ |
| Oaktree Specialty Lending Corp | 10% Owner | J Other deriv | 2023-11-30 | 2023-12-04 | 445,294 | — | $0 | 3,117,057 | SEC↗ |
| Oaktree AZ Strategic Lending F | 10% Owner | J Other deriv | 2023-11-30 | 2023-12-04 | 445,294 | — | $0 | 3,117,057 | SEC↗ |
| BROOKFIELD Corp /ON/ | 10% Owner | J Other deriv | 2023-11-30 | 2023-12-04 | 445,294 | — | $0 | 3,117,057 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2023-06-16 | 2023-06-20 | 13,222 | — | $0 | 13,222 | SEC↗ |
| NELSON TIMOTHY S | Director | A Award deriv | 2023-06-16 | 2023-06-20 | 13,222 | — | $0 | 13,222 | SEC↗ |
| SHAH MAHENDRA | Director | A Award deriv | 2023-06-16 | 2023-06-20 | 13,222 | — | $0 | 13,222 | SEC↗ |
| Wilfong Diane E. | Director | A Award deriv | 2023-06-16 | 2023-06-20 | 13,222 | — | $0 | 13,222 | SEC↗ |
| Cline Darren S | Director | A Award deriv | 2023-06-16 | 2023-06-20 | 13,222 | — | $0 | 13,222 | SEC↗ |
| Kalb Michael Wayne | CFO | A Award deriv | 2023-05-10 | 2023-05-12 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Kalb Michael Wayne | CFO | A Award deriv | 2023-05-10 | 2023-05-12 | 47,500 | — | $0 | 47,500 | SEC↗ |
| Cline Darren S | Director | A Award deriv | 2023-04-12 | 2023-04-14 | 20,013 | — | $0 | 20,013 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | A Award deriv | 2023-02-14 | 2023-02-16 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | A Award deriv | 2023-02-14 | 2023-02-16 | 70,000 | — | $0 | 70,000 | SEC↗ |
| Hoekman John | Chief Scientific Officer | A Award deriv | 2023-02-14 | 2023-02-16 | 42,500 | — | $0 | 42,500 | SEC↗ |
| Paolillo Leonard | Chief Commercial Officer | A Award deriv | 2023-02-14 | 2023-02-16 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | M Exercise deriv | 2022-12-31 | 2023-01-04 | 10,571 | — | $0 | 0 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | F Tax w/h | 2022-12-31 | 2023-01-04 | 3,627 | $3.75 | $13.6K | 6,944 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | M Exercise | 2022-12-31 | 2023-01-04 | 10,571 | — | $0 | 10,571 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 12,789 | — | $0 | 12,789 | SEC↗ |
| PARKER H STEWART | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 12,789 | — | $0 | 12,789 | SEC↗ |
| NELSON TIMOTHY S | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 12,789 | — | $0 | 12,789 | SEC↗ |
| SHAH MAHENDRA | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 12,789 | — | $0 | 12,789 | SEC↗ |
| Wilfong Diane E. | Director | A Award deriv | 2022-06-16 | 2022-06-17 | 12,789 | — | $0 | 12,789 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise deriv | 2022-03-29 | 2022-03-30 | 24,606 | — | $0 | 0 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise | 2022-03-29 | 2022-03-30 | 24,606 | $1.97 | $48.5K | 97,990 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | A Award deriv | 2022-01-26 | 2022-01-28 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Hoekman John | Chief Scientific Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 35,000 | — | $0 | 35,000 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | A Award deriv | 2022-01-26 | 2022-01-28 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Paolillo Leonard | Chief Commercial Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 40,000 | — | $0 | 40,000 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | A Award deriv | 2022-01-26 | 2022-01-28 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Hoekman John | Chief Scientific Officer | M Exercise deriv | 2021-12-22 | 2021-12-23 | 20,000 | — | $0 | 0 | SEC↗ |
| Hoekman John | Chief Scientific Officer | M Exercise | 2021-12-22 | 2021-12-23 | 20,000 | $1.64 | $32.8K | 128,221 | SEC↗ |
| NELSON TIMOTHY S | Director | P Buy | 2021-11-19 | 2021-11-22 | 10,000 | $10.76 | $107.6K | 10,000 | SEC↗ |
| Leaman John Harold | Chief Fin. & Business Office | A Award deriv | 2021-10-19 | 2021-10-21 | 10,571 | — | $0 | 10,571 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise deriv | 2021-09-21 | 2021-09-22 | 14,780 | — | $0 | 0 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise deriv | 2021-09-21 | 2021-09-22 | 4,650 | — | $0 | 541 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise deriv | 2021-09-21 | 2021-09-22 | 53,954 | — | $0 | 29,587 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise | 2021-09-21 | 2021-09-22 | 14,780 | $1.97 | $29.1K | 14,780 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise | 2021-09-21 | 2021-09-22 | 4,650 | $2.46 | $11.4K | 19,430 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | M Exercise | 2021-09-21 | 2021-09-22 | 53,954 | $2.95 | $159.2K | 73,384 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | P Buy | 2021-08-18 | 2021-08-19 | 600 | $15.89 | $9.5K | 20,000 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | P Buy | 2021-08-18 | 2021-08-19 | 2,197 | $14.91 | $32.8K | 19,400 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | P Buy | 2021-08-18 | 2021-08-19 | 17,203 | $13.81 | $237.6K | 17,203 | SEC↗ |
| ADAMS ADRIAN | COB, CEO and President | A Award deriv | 2021-07-20 | 2021-07-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Hoekman John | Chief Scientific Officer | A Award deriv | 2021-07-20 | 2021-07-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Leaman John Harold | Chief Financial Officer | A Award deriv | 2021-07-20 | 2021-07-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Paolillo Leonard | Chief Commercial Officer | A Award deriv | 2021-07-20 | 2021-07-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SHREWSBURY STEPHEN B | Chief Medical Officer | A Award deriv | 2021-07-20 | 2021-07-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| Allison David D. | Director | A Award deriv | 2021-07-11 | 2021-07-13 | 11,500 | — | $0 | 11,500 | SEC↗ |
| NELSON TIMOTHY S | Director | A Award deriv | 2021-07-11 | 2021-07-13 | 11,500 | — | $0 | 11,500 | SEC↗ |
| PARKER H STEWART | Director | A Award deriv | 2021-07-11 | 2021-07-13 | 11,500 | — | $0 | 11,500 | SEC↗ |
| SHAH MAHENDRA | Director | A Award deriv | 2021-07-11 | 2021-07-13 | 11,500 | — | $0 | 11,500 | SEC↗ |
| Wilfong Diane E. | Director | A Award deriv | 2021-07-11 | 2021-07-13 | 11,500 | — | $0 | 11,500 | SEC↗ |
| KRAVIS HENRY R | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 42,307,448 | — | $0 | 0 | SEC↗ |
| Hoekman John | Chief Scientific Officer | C Conversion deriv | 2021-04-27 | 2021-04-29 | 69,657 | — | $0 | 0 | SEC↗ |
| Hoekman John | Chief Scientific Officer | X Exercise deriv | 2021-04-27 | 2021-04-29 | 8,523 | $8.19 | $69.8K | 0 | SEC↗ |
| Hoekman John | Chief Scientific Officer | X Exercise deriv | 2021-04-27 | 2021-04-29 | 8,523 | — | $0 | 69,657 | SEC↗ |
| PARKER H STEWART | Director | C Conversion deriv | 2021-04-27 | 2021-04-29 | 0 | — | $0 | 0 | SEC↗ |
| PARKER H STEWART | Director | C Conversion deriv | 2021-04-27 | 2021-04-29 | 143,986 | — | $0 | 0 | SEC↗ |
| PARKER H STEWART | Director | X Exercise deriv | 2021-04-27 | 2021-04-29 | 47,236 | — | $0 | 143,986 | SEC↗ |
| PARKER H STEWART | Director | X Exercise deriv | 2021-04-27 | 2021-04-29 | 47,263 | $8.66 | $409.3K | 0 | SEC↗ |
| PARKER H STEWART | Director | C Conversion deriv | 2021-04-27 | 2021-04-29 | 120,447 | — | $0 | 0 | SEC↗ |
| PARKER H STEWART | Director | X Exercise deriv | 2021-04-27 | 2021-04-29 | 13,756 | — | $0 | 120,447 | SEC↗ |
| PARKER H STEWART | Director | X Exercise deriv | 2021-04-27 | 2021-04-29 | 13,756 | $8.19 | $112.7K | 0 | SEC↗ |
| PARKER H STEWART | Director | C Conversion deriv | 2021-04-27 | 2021-04-29 | 61,109 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 8,845,942 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 8,201,930 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 13,233,885 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 0 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 5,876,034 | — | $0 | 0 | SEC↗ |
| Kossow Jon Erik | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 35,256,206 | — | $0 | 0 | SEC↗ |
| Kossow Jon Erik | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 0 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 5,876,034 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 13,233,885 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 8,845,942 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 8,201,930 | — | $0 | 0 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 1,359,799 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 11,628,174 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 5,162,969 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 995,714 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 7,206,216 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 713,064 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 0 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 0 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 1,073,308 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 7,772,634 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion deriv | 2021-04-27 | 2021-04-29 | 1,605,711 | — | $0 | 0 | SEC↗ |
| Hoekman John | Chief Scientific Officer | C Conversion deriv | 2021-04-27 | 2021-06-07 | 69,657 | — | $0 | 0 | SEC↗ |
| KRAVIS HENRY R | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 1,100,000 | $15.00 | $16.50M | 3,802,638 | SEC↗ |
| KRAVIS HENRY R | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 2,583,926 | — | $0 | 2,583,926 | SEC↗ |
| KRAVIS HENRY R | 10% Owner | J Other | 2021-04-27 | 2021-04-29 | 118,712 | $13.50 | $1.60M | 2,702,638 | SEC↗ |
| Hoekman John | Chief Scientific Officer | C Conversion | 2021-04-27 | 2021-04-29 | 4,523 | — | $0 | 108,496 | SEC↗ |
| Hoekman John | Chief Scientific Officer | J Other | 2021-04-27 | 2021-04-29 | 275 | — | $0 | 108,221 | SEC↗ |
| PARKER H STEWART | Director | J Other | 2021-04-27 | 2021-04-29 | 1,666 | — | $0 | 17,756 | SEC↗ |
| PARKER H STEWART | Director | C Conversion | 2021-04-27 | 2021-04-29 | 271 | $13.50 | $3.7K | 18,027 | SEC↗ |
| PARKER H STEWART | Director | C Conversion | 2021-04-27 | 2021-04-29 | 8,793 | — | $0 | 19,422 | SEC↗ |
| PARKER H STEWART | Director | J Other | 2021-04-27 | 2021-04-29 | 458 | — | $0 | 10,629 | SEC↗ |
| PARKER H STEWART | Director | C Conversion | 2021-04-27 | 2021-04-29 | 7,355 | — | $0 | 11,087 | SEC↗ |
| PARKER H STEWART | Director | C Conversion | 2021-04-27 | 2021-04-29 | 3,732 | — | $0 | 3,732 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 2,309,791 | — | $0 | 2,309,791 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 450,000 | $15.00 | $6.75M | 2,759,791 | SEC↗ |
| Kossow Jon Erik | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 2,153,271 | — | $0 | 2,252,198 | SEC↗ |
| Kossow Jon Erik | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 825,000 | $15.00 | $12.38M | 3,077,198 | SEC↗ |
| Kossow Jon Erik | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 98,927 | $13.50 | $1.34M | 98,927 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 358,878 | — | $0 | 2,208,334 | SEC↗ |
| PARMAR KUSH | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 575,000 | $15.00 | $8.63M | 575,000 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 101,457 | $13.50 | $1.37M | 2,309,791 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 500,932 | — | $0 | 1,849,456 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 540,265 | — | $0 | 1,348,524 | SEC↗ |
| PARMAR KUSH | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 808,259 | — | $0 | 808,259 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 69,380 | $15.00 | $1.04M | 349,674 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | P Buy | 2021-04-27 | 2021-04-29 | 505,620 | $15.00 | $7.58M | 2,535,115 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 12,311 | $13.50 | $166.2K | 280,294 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 89,145 | $13.50 | $1.20M | 2,029,495 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 43,550 | — | $0 | 267,983 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 315,328 | — | $0 | 1,940,350 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 60,813 | — | $0 | 224,433 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 440,119 | — | $0 | 1,625,022 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 65,552 | — | $0 | 163,620 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 474,713 | — | $0 | 1,184,903 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 98,068 | — | $0 | 98,068 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | C Conversion | 2021-04-27 | 2021-04-29 | 710,190 | — | $0 | 710,190 | SEC↗ |
| Hoekman John | Chief Scientific Officer | C Conversion | 2021-04-27 | 2021-06-07 | 4,253 | — | $0 | 108,496 | SEC↗ |
| ROCKLAGE SCOTT M | 10% Owner | J Other deriv | 2021-04-22 | 2021-04-26 | 1,359,799 | — | $0 | 1,359,799 | SEC↗ |
| PARKER H STEWART | Director | J Other deriv | 2021-04-22 | 2021-04-26 | 0 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | J Other deriv | 2021-04-22 | 2021-04-26 | 0 | — | $0 | 0 | SEC↗ |
| Vivo Capital Surplus Fund VIII | 10% Owner | J Other deriv | 2021-04-22 | 2021-04-26 | 0 | — | $0 | 0 | SEC↗ |
| HAQUE PROMOD | 10% Owner | J Other deriv | 2021-04-22 | 2021-04-26 | 0 | — | $0 | 0 | SEC↗ |
| venBio Global Strategic Fund I | 10% Owner | J Other deriv | 2021-04-22 | 2021-04-26 | 0 | — | $0 | 0 | SEC↗ |